DiagnosTear Partners with AlyaTec for Clinical Validation of Revolutionary Red Eye Diagnostic Test
Key Insights
DiagnosTear Technologies has initiated a clinical collaboration with AlyaTec to advance the analytical validation of TeaRx™ Red Eye, the first rapid multi-biomarker diagnostic test designed to differentiate between three major red eye conditions at the point of care.
The study will enroll 30 documented allergy patients and examine tear IgE (search) levels before and after controlled ocular allergy provocation to validate the diagnostic test's accuracy for allergic conjunctivitis (search) detection.
TeaRx™ Red Eye addresses a significant unmet medical need, as these three conditions drive hundreds of millions of clinic visits annually yet misdiagnosis remains widespread due to the absence of fast, accurate testing methods.
DiagnosTear Technologies Inc. (search) has announced a strategic collaboration with AlyaTec, a globally renowned Contract Research Organization specializing in allergy and environmental diseases, to initiate a clinical study that will advance the analytical validation and FDA submission pathway for TeaRx™ Red Eye diagnostic test.
Revolutionary Multi-Biomarker Diagnostic Platform
TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis (search), Herpetic keratitis (search), and Allergic conjunctivitis (search) at the point of care. These three conditions drive hundreds of millions of clinic visits every year, yet misdiagnosis remains widespread due to the absence of fast, accurate testing. TeaRx™ aims to change that with a simple test that delivers clinical answers in minutes.
Clinical Study Design and Methodology
The new study with AlyaTec will examine documented allergy patients and collect tear samples before and after a controlled provocation of ocular allergy. Thirty patients are planned for enrollment, with approvals and site setup expected to take approximately 3 months, followed by 2-3 months of patient recruitment.
All samples will undergo independent, quantitative testing of total tear IgE (search), and results will be compared to DiagnosTear's TeaRx™ Red Eye assay. This work is designed to finalize the validation, and the analytical characterization of tear IgE as a biomarker for allergic conjunctivitis (search) and to reinforce the Company's scientific case for its comprehensive Red Eye diagnostic panel.
Clinical Impact and Commercial Potential
"This collaboration with AlyaTec represents a strong accelerator for our Red Eye program," said Dr. Shimon Gross, CEO of DiagnosTear. "Accurate differentiation of red eye conditions has been a long-standing unmet need. Our goal is to deliver a test that gives clinicians immediate clarity, improves patient management, and reduces unnecessary treatments. This study moves us significantly closer to that vision."
Dr. Gross added: "With the AlyaTec collaboration now underway, we believe TeaRx™ Red Eye is positioned to become one of the most clinically impactful and commercially significant innovations in ophthalmic diagnostics."
Regulatory Pathway and Future Development
Pending successful validation, DiagnosTear plans to advance additional clinical trials to support FDA clearance and prepare for global commercialization. The collaboration with AlyaTec, known for its sophisticated clinical models and translational expertise in allergy research, provides the specialized expertise needed to validate tear-based biomarkers for allergic conjunctivitis (search).
DiagnosTear Technologies Inc. (search) positions itself as a global leader in rapid, point-of-care diagnostics for ocular diseases. The Company develops multi-parametric tests that provide fast, clinically actionable insights based on tear fluid analysis, with a mission to transform ophthalmic care with accessible diagnostics that support precise, data-driven decision making.